Q BioMed Past Earnings Performance
Past criteria checks 0/6
Q BioMed has been growing earnings at an average annual rate of 77.6%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 22.7% per year.
Key information
77.6%
Earnings growth rate
90.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -22.7% |
| Return on equity | n/a |
| Net Margin | -912.1% |
| Last Earnings Update | 28 Feb 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Q BioMed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 28 Feb 23 | 0 | -2 | 3 | 0 |
| 30 Nov 22 | 0 | -3 | 3 | 0 |
| 31 Aug 22 | 0 | -8 | 4 | 1 |
| 31 May 22 | 0 | -8 | 5 | 1 |
| 28 Feb 22 | 0 | -9 | 5 | 1 |
| 30 Nov 21 | 0 | -9 | 6 | 1 |
| 31 Aug 21 | 0 | -10 | 7 | 2 |
| 31 May 21 | 0 | -11 | 7 | 2 |
| 28 Feb 21 | 0 | -11 | 8 | 2 |
| 30 Nov 20 | 0 | -14 | 11 | 2 |
| 31 Aug 20 | 0 | -13 | 10 | 2 |
| 31 May 20 | 0 | -13 | 9 | 2 |
| 29 Feb 20 | 0 | -14 | 9 | 3 |
| 30 Nov 19 | 0 | -10 | 4 | 4 |
| 31 Aug 19 | 0 | -10 | 5 | 3 |
| 31 May 19 | 0 | -10 | 6 | 3 |
| 28 Feb 19 | 0 | -9 | 6 | 3 |
| 30 Nov 18 | 0 | -9 | 6 | 3 |
| 31 Aug 18 | 0 | -11 | 8 | 3 |
| 31 May 18 | 0 | -12 | 9 | 3 |
| 28 Feb 18 | 0 | -13 | 9 | 3 |
| 30 Nov 17 | 0 | -15 | 9 | 3 |
| 31 Aug 17 | 0 | -13 | 8 | 3 |
| 31 May 17 | 0 | -10 | 6 | 3 |
| 28 Feb 17 | 0 | -8 | 5 | 2 |
| 30 Nov 16 | 0 | -7 | 5 | 1 |
| 31 Aug 16 | 0 | -6 | 4 | 1 |
| 31 May 16 | 0 | -4 | 3 | 1 |
| 29 Feb 16 | 0 | -3 | 2 | 1 |
| 30 Nov 15 | 0 | -1 | 0 | 1 |
| 31 Aug 15 | 0 | 0 | 0 | 0 |
| 31 May 15 | 0 | 0 | 0 | 0 |
| 28 Feb 15 | 0 | 0 | 0 | 0 |
Quality Earnings: QBIO is currently unprofitable.
Growing Profit Margin: QBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if QBIO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare QBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: QBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.